$4.36
1.63% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Inozyme Pharma Inc Stock News

Neutral
GlobeNewsWire
10 days ago
- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -
Neutral
GlobeNewsWire
17 days ago
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) rec...
Neutral
GlobeNewsWire
27 days ago
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief...
Neutral
GlobeNewsWire
2 months ago
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at ...
Positive
Seeking Alpha
3 months ago
Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use of INZ-701 for the treatment of patients with ABCC6 Deficiency. Meeting with FDA to discuss potential of initiating a pivotal late-stage study u...
Neutral
GlobeNewsWire
3 months ago
- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT -
Neutral
GlobeNewsWire
4 months ago
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
Neutral
GlobeNewsWire
4 months ago
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today